{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:20:39Z","timestamp":1774974039817,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50MH100023"],"award-info":[{"award-number":["P50MH100023"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P51OD11132"],"award-info":[{"award-number":["P51OD11132"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105886","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T02:48:29Z","timestamp":1631760509000},"page":"105886","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging"],"prefix":"10.1016","volume":"173","author":[{"given":"Achi","family":"Haider","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard S.","family":"Van","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuo","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perla","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Appu","family":"Aravind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9337-341X","authenticated-orcid":false,"given":"Yihan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongzhao","family":"Ran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven H.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1677\/joe.0.1560223","article-title":"Structural bases of vasopressin\/oxytocin receptor function","volume":"156","author":"Barberis","year":"1998","journal-title":"J. Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1053\/j.jvca.2009.09.006","article-title":"Vasopressin: a review of therapeutic applications","volume":"24","author":"Holt","year":"2010","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.phrs.2021.105886_bib3","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev.pa.30.040190.002441","article-title":"Conformational and structural considerations in oxytocin-receptor binding and biological activity","volume":"30","author":"Hruby","year":"1990","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1152\/physrev.00035.2011","article-title":"Vasopressin V1a and V1b receptors: from molecules to physiological systems","volume":"92","author":"Koshimizu","year":"2012","journal-title":"Physiol. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2021.105886_bib5","first-page":"35","article-title":"[Vasopressin and oxytocin receptors in the central nervous system of the rat]","volume":"46","author":"Barberis","year":"1985","journal-title":"Ann. D. \u2019Endocrinol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105886_bib6","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1152\/ajpendo.00148.2003","article-title":"Gal, Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas","volume":"285","author":"Folny","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105886_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.neuroscience.2014.04.055","article-title":"Neuroanatomical distribution of oxytocin and vasopressin 1a receptors in the socially monogamous coppery titi monkey (Callicebus cupreus)","volume":"273","author":"Freeman","year":"2014","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12382","article-title":"Comparative perspectives on oxytocin and vasopressin receptor research in rodents and primates: translational implications","volume":"28","author":"Freeman","year":"2016","journal-title":"J. Neuroendocrinol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1365-2826.1999.00332.x","article-title":"Localization of vasopressin (V1a) receptor binding and mRNA in the rhesus monkey brain","volume":"11","author":"Young","year":"1999","journal-title":"J. Neuroendocrinol."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2021.105886_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0167-0115(99)00059-2","article-title":"Characterization of rodent liver and kidney AVP receptors: pharmacologic evidence for species differences","volume":"84","author":"Tahara","year":"1999","journal-title":"Regul. Pept."},{"key":"10.1016\/j.phrs.2021.105886_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110060","article-title":"Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor","volume":"126","author":"Pierce","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.phrs.2021.105886_bib12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/sj.mp.4001503","article-title":"Examination of AVPR1a as an autism susceptibility gene","volume":"9","author":"Wassink","year":"2004","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2021.105886_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2040-2392-2-3","article-title":"Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism","volume":"2","author":"Tansey","year":"2011","journal-title":"Mol. Autism"},{"issue":"6","key":"10.1016\/j.phrs.2021.105886_bib14","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1002\/jps.23495","article-title":"Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist","volume":"102","author":"Fabio","year":"2013","journal-title":"J. Pharm. Sci."},{"issue":"11","key":"10.1016\/j.phrs.2021.105886_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113682","article-title":"Safety and tolerability of SRX246, a vasopressin 1a antagonist, in irritable Huntington\u2019s disease patients-A randomized phase 2 clinical trial","volume":"9","author":"Brownstein","year":"2020","journal-title":"J. Clin. Med"},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib16","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2005-1453","article-title":"Evidence for a role of vasopressin in the control of aldosterone secretion in primary aldosteronism: in vitro and in vivo studies","volume":"91","author":"Perraudin","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/00016340500495082","article-title":"Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea","volume":"85","author":"Liedman","year":"2006","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2021.105886_bib18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(02)01813-7","article-title":"Pharmacological characterization of YM471, a novel potent vasopressin V(1A) and V(2) receptor antagonist","volume":"446","author":"Tsukada","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2021.105886_bib19","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.bmc.2006.12.031","article-title":"Azetidinones as vasopressin V1a antagonists","volume":"15","author":"Guillon","year":"2007","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00213-008-1354-x","article-title":"Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior","volume":"202","author":"Bleickardt","year":"2009","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2021.105886_bib21","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2006.03.055","article-title":"Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells","volume":"538","author":"Tahara","year":"2006","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105886_bib22","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.vph.2007.02.001","article-title":"Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy","volume":"46","author":"Tahara","year":"2007","journal-title":"Vasc. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105886_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1172\/JCI116554","article-title":"Fur, et al., Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors","volume":"92","author":"Serradeil-Le Gal","year":"1993","journal-title":"J. Clin. Investig."},{"issue":"5","key":"10.1016\/j.phrs.2021.105886_bib24","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1471-0528.2000.tb13302.x","article-title":"Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea","volume":"107","author":"Brouard","year":"2000","journal-title":"Bjog"},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/09513590400021144","article-title":"The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor","volume":"20","author":"Steinwall","year":"2005","journal-title":"Gynecol. Endocrinol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105886_bib26","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1021\/jm501745f","article-title":"Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach","volume":"58","author":"Ratni","year":"2015","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.phrs.2021.105886_bib27","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/npp.2017.92","article-title":"A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (Rg7713) in high-functioning adults with autism spectrum disorder","volume":"42","author":"Umbricht","year":"2017","journal-title":"Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105886_bib28","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","article-title":"Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder","volume":"63","author":"Schnider","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2021.105886_bib29","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1021\/cr0782426","article-title":"Molecular imaging with PET","volume":"108","author":"Ametamey","year":"2008","journal-title":"Chem. Rev."},{"issue":"7","key":"10.1016\/j.phrs.2021.105886_bib30","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd2290","article-title":"Molecular imaging in drug development","volume":"7","author":"Willmann","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1007","article-title":"Molecular imaging in drug discovery and development","volume":"2","author":"Rudin","year":"2003","journal-title":"Nat. Rev. Drug Disco"},{"key":"10.1016\/j.phrs.2021.105886_bib32","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bmc.2011.12.013","article-title":"Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging","volume":"20","author":"Fabio","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2021.105886_bib33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ejmech.2017.08.037","article-title":"Development of a radioligand for imaging V(1a) vasopressin receptors with PET","volume":"139","author":"Naik","year":"2017","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2021.105886_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.28250","article-title":"Vasopressin 1a receptor partial agonism increases sodium excretion and reduces portal hypertension and ascites in cirrhotic rats","volume":"63","author":"Fern\u00e1ndez-Varo","year":"2016","journal-title":"Hepatology"},{"issue":"15","key":"10.1016\/j.phrs.2021.105886_bib35","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00018-006-6054-2","article-title":"Vasopressin antagonists","volume":"63","author":"Lemmens-Gruber","year":"2006","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2021.105886_bib36","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biochi.2019.01.008","article-title":"Vasopressin receptors in islets enhance glucose tolerance, pancreatic beta-cell secretory function, proliferation and survival","volume":"158","author":"Mohan","year":"2019","journal-title":"Biochimie"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2021.105886_bib37","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.regpep.2009.12.015","article-title":"Age-dependent role of vasopressin in susceptibility of gastric mucosa to indomethacin-induced injury","volume":"161","author":"Zelena","year":"2010","journal-title":"Regul. Pept."},{"issue":"19","key":"10.1016\/j.phrs.2021.105886_bib38","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1016\/j.bmcl.2011.08.038","article-title":"Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability","volume":"21","author":"Johnson","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"13","key":"10.1016\/j.phrs.2021.105886_bib40","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.phrs.2021.105886_bib41","series-title":"AMBER 2020","author":"Case","year":"2020"},{"issue":"6369","key":"10.1016\/j.phrs.2021.105886_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/356523a0","article-title":"Molecular cloning and expression of a rat V1a arginine vasopressin receptor","volume":"356","author":"Morel","year":"1992","journal-title":"Nature"},{"issue":"2\u20133","key":"10.1016\/j.phrs.2021.105886_bib43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2006.12.010","article-title":"Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice","volume":"559","author":"Hiroyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"20","key":"10.1016\/j.phrs.2021.105886_bib44","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1073\/pnas.0600875103","article-title":"V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity","volume":"103","author":"Koshimizu","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2021.105886_bib45","first-page":"G321","article-title":"Vasopressin modulates liver regeneration in the Brattleboro rat","volume":"245","author":"Russell","year":"1983","journal-title":"Am. J. Physiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105886_bib46","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0168-8278(03)00116-8","article-title":"Effect of the V1a\/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites","volume":"38","author":"Fern\u00e1ndez-Varo","year":"2003","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105886_bib47","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/CIRCULATIONAHA.111.021352","article-title":"Controlled and cardiac-restricted overexpression of the arginine vasopressin V1A receptor causes reversible left ventricular dysfunction through G\u03b1q-mediated cell signaling","volume":"124","author":"Li","year":"2011","journal-title":"Circulation"},{"issue":"2 Pt 1","key":"10.1016\/j.phrs.2021.105886_bib48","first-page":"E217","article-title":"Vasopressin V1 and V2 receptors in diabetes mellitus","volume":"266","author":"Trinder","year":"1994","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105886_bib49","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1210\/en.2006-1315","article-title":"Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice","volume":"148","author":"Aoyagi","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2021.105886_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.tetlet.2021.153007","article-title":"Imaging the trace amine-associated receptor 1 by positron emission tomography","volume":"70","author":"Sun","year":"2021","journal-title":"Tetrahedron Lett."},{"issue":"3","key":"10.1016\/j.phrs.2021.105886_bib51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41401-020-0456-9","article-title":"Synthesis and preliminary evaluation of novel (11)C-labeled GluN2B-selective NMDA receptor negative allosteric modulators","volume":"42","author":"Sun","year":"2021","journal-title":"Acta Pharm. Sin."},{"issue":"24","key":"10.1016\/j.phrs.2021.105886_bib52","doi-asserted-by":"crossref","first-page":"11178","DOI":"10.7150\/thno.42587","article-title":"Synthesis and preliminary studies of (11)C-labeled tetrahydro-1,7-naphthyridine-2-carboxamides for PET imaging of metabotropic glutamate receptor 2","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.phrs.2021.105886_bib53","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2967\/jnumed.118.221051","article-title":"Preclinical evaluation of benzazepine-based PET radioligands (R)- and (S)-(11)C-Me-NB1 reveals distinct enantiomeric binding patterns and a tightrope walk between GluN2B- and \u03c3(1)-receptor-targeted PET imaging","volume":"60","author":"Haider","year":"2019","journal-title":"J. Nucl. Med"},{"issue":"6","key":"10.1016\/j.phrs.2021.105886_bib54","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1021\/acs.jmedchem.7b01400","article-title":"In vitro and in vivo evaluation of (11)C-labeled azetidinecarboxylates for imaging monoacylglycerol lipase by PET imaging studies","volume":"61","author":"Cheng","year":"2018","journal-title":"J. Med. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821004709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T20:48:51Z","timestamp":1734382131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821004709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":54,"alternative-id":["S1043661821004709"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105886","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.09.430516","asserted-by":"object"}]},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a triazolobenzodiazepine-based PET probe for subtype-selective vasopressin 1A receptor imaging","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105886","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105886"}}